Dyne Therapeutics Quarterly Cash Flow Statement
NASDAQ: DYNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.64+0.27 (+1.65%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Dyne Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Dyne Therapeutics generated -$130.3 million of operating cash flow and spent $1.5 million on capital expenditures. That left free cash flow of -$131.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Dyne Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -178.56M | -120.85M | -111.95M | -108.04M | -110.86M | -115.36M | -89.54M | -97.13M | -65.10M | -65.65M | -66.64M | -60.21M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 600.00K | 550.00K | 521.00K | 500.00K | 500.00K | 502.00K | 450.00K | 400.00K | 400.00K | 386.00K | 399.00K | 400.00K |
| Stock-Based Compensation | 14.98M | 13.08M | 11.23M | 11.08M | 10.52M | 13.02M | 10.48M | 8.74M | 6.74M | 19.91M | 5.73M | 4.88M |
| Change in Working Capital | 9.48M | -32.85M | -2.20M | 389.00K | -2.20M | 5.00M | -4.09M | 765.00K | -3.14M | -4.07M | 4.12M | -4.96M |
| Operating Cash Flow | -130.29M | -144.92M | -111.83M | -90.78M | -94.70M | -105.89M | -84.33M | -74.63M | -54.87M | -78.54M | -35.01M | -50.60M |
| Capital Expenditures | -1.51M | -221.00K | -484.00K | -395.00K | -60.00K | -981.00K | -1.07M | -253.00K | -857.00K | -191.00K | -82.00K | -167.00K |
| Investing Cash Flow | -4.79M | -2.39M | 982.00K | -37.97M | 6.77M | 1.46M | -16.01M | -19.40M | 11.17M | -179.84M | 26.20M | 12.82M |
| Debt Issued | — | — | 49.45M | 0 | — | — | 0 | 0 | — | — | — | — |
| Financing Cash Flow | 58.11M | 7.06M | 430.96M | 217.33M | 100.77M | 141.24M | 3.64M | 18.01M | 379.86M | 408.39M | 147.00K | 454.00K |
| Net Change in Cash | -76.97M | -140.25M | 320.12M | 88.58M | 12.85M | 36.81M | -96.71M | -76.02M | 336.17M | 150.01M | -8.66M | -37.33M |
| Free Cash Flow | -131.80M | -145.14M | -112.32M | -91.17M | -94.76M | -106.87M | -85.41M | -74.88M | -55.73M | -78.73M | -35.09M | -50.77M |
This table shows 12 quarterly periods of Dyne Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow DYN's reporting calendar. What is a cash flow statement?